Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

184.88 -0.29 (-0.16%)

Streaming Delayed Price Updated: 2:09 PM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views ↗

March 27, 2025

Via Benzinga

Why Pharma and Biotech Stocks Got Thrashed on Tuesday ↗

March 25, 2025

Via The Motley Fool

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. ↗

March 25, 2025

The company is working on a non-stimulant approach to treating ADHD.

Via Investor's Business Daily

Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal ↗

March 25, 2025

Axsome's solriamfetol met primary and key secondary endpoints in a Phase 3 ADHD trial, showing significant symptom reduction and a favorable safety profile.

Via Benzinga

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

March 25, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings) ↗

February 27, 2025

Via Benzinga

Beyond The Numbers: 17 Analysts Discuss Axsome Therapeutics Stock ↗

February 10, 2025

Via Benzinga

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

March 05, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

March 03, 2025

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Participate in Upcoming Investor Conferences

February 26, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs ↗

February 24, 2025

Axsome's Symbravo outperformed oral CGRP inhibitors in a Phase 3 trial, improving migraine pain relief, symptom control, and return to daily activities.

Via Benzinga

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

February 24, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride ↗

February 18, 2025

CEO Herriot Tabuteau struck an optimistic tone, citing strong commercial growth, a rapidly advancing pipeline, and the recent U.S. approval of Symbravo for migraine treatment.

Via Stocktwits

US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday? ↗

February 18, 2025

Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday.

Via Benzinga

Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst ↗

February 18, 2025

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Via Benzinga

Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript ↗

February 18, 2025

AXSM earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Axsome Therapeutics Revenue Surges 66% ↗

February 18, 2025

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated losses.

Via The Motley Fool

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 18, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Via Benzinga

Earnings Scheduled For February 18, 2025 ↗

February 18, 2025

Via Benzinga

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy? ↗

February 16, 2025

Via The Motley Fool

Why Axsome Therapeutics Stock Is Soaring Today ↗

February 11, 2025

Via The Motley Fool

Why Axsome Therapeutics Stock Is Skyrocketing Today ↗

February 10, 2025

Via The Motley Fool

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' ↗

February 10, 2025

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Via Benzinga

Topics Intellectual Property

Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday ↗

February 10, 2025

Via Benzinga

Axsome Stock Rockets To Record High After Settling With Teva Over Depression Drug, Retail Optimism Swells ↗

February 10, 2025

Under the settlement terms, Teva will receive a license to sell a generic version of Auvelity starting March 31, 2039, if pediatric exclusivity is granted.

Via Stocktwits

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

February 10, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

January 31, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

January 30, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

January 22, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.